Cloverleaf Bio
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio announced $33M in Seed financing on September 8, 2026. Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
Round details
The financing includes backing from 4BIO Capital, AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund. The company did not publish a valuation with the announcement.
- Round: Seed
- Capital announced: $33M
- Headquarters: New Haven, CT
How the company plans to use the capital
Cloverleaf Bio will advance an inhibitory tRNA program for hepatocellular carcinoma into early clinical testing and move an antibody-tRNA conjugate program for colorectal cancer through preclinical development.
Why this matters for GTM teams
The participation of three pharmaceutical investors at the preclinical stage indicates industry interest in engineered tRNA as a programmable therapeutic payload rather than only a research tool.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Cloverleaf Bio seed announcement.
Company Info
Investors (4)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free